The Cancer Center Administration staff is responsible for the administrative, fiscal, information and facilities management that support the research efforts of the Cancer Center. Ms. Janet Villarmia is the chief administrative and financial officer of the USC Norris Comprehensive Cancer Center (NCCC). As the Associate Director for Administration and Education and a senior leader of the Cancer Center, she is a member of the Executive Committee and the Cancer Center Leadership Council. Ms. Villarmia has primary responsibility for the management of the Cancer Center Support Grant (CCSG). She supervises the work of the Cancer Center Business Office and the Cancer Center Administrative Office. Ms. Villarmia's other administrative responsibilities include oversight of the Cancer Research Informatics Core, Facilities Management, the Patient Education and Community Outreach Center, the Cancer Survivorship Advisory Council and membership on the Informatics Working Group. She oversees, in overlap with the other Associate Directors, the operations of the CCSG funded shared resources. The Cancer Center Business Office is responsible for the day-to-day accounting of all the CCSG budgets as well as the management of the research and gift accounts of many of the investigators housed in NCCC space. The office consists of a Senior Business Officer and 5.6 FTE accountants and analysts. The primary business goal of the Cancer Center Business Office is to promote a business environment that maximizes research and minimizes administrative burden for NCCC investigators and lab personnel without compromising solid stewardship of funds. The personnel in the Cancer Center Administrative Office provide administrative and secretarial support to the Cancer Center Director and the various Associate Directors, research program leaders, shared resources directors as well as to various NCCC committees and advisory groups. They organize NCCC seminars, retreats, conferences, meetings, and poster sessions. We are requesting $598,180 in the first year to support the Cancer Center Administration, which represents 20% of the annual total cost of the administration and 9% ofthe total Year 1 CCSG budget.
The Cancer Center Administration fosters the development of more effective prevention, diagnosis, treatment of cancer by providing the administrative, fiscal, information, and facilities management to support the cancer research efforts of NCCC investigators.
|Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734|
|Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994|
|Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207|
|Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22|
|Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472|
|Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48|
|Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195|
|Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184|
|Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244|
|Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121|
Showing the most recent 10 out of 842 publications